Lead Product(s) : Enzastaurin
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Aytu BioPharma Announces Issuance of Its First Patent for AR101/Enzastaurin
Details : AR101 (enzastaurin) is an orally available investigational first-in-class small molecule, serine/threonine kinase inhibitor of the PKC beta, PI3K and AKT pathways.
Brand Name : AR101
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 16, 2022
Lead Product(s) : Enzastaurin
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Enzastaurin
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Canaccord Genuity
Deal Size : $10.0 million
Deal Type : Public Offering
Aytu BioPharma Announces Closing of $10.0 Million Registered Public Offering
Details : The Company intends to use the net proceeds from the Offering for advancing the development of its pipeline assets, including for advancing the PREVEnt Trial evaluating AR101 for the treatment of vascular Ehlers-Danlos Syndrome (VEDS).
Brand Name : AR101
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 15, 2022
Lead Product(s) : Enzastaurin
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Canaccord Genuity
Deal Size : $10.0 million
Deal Type : Public Offering
Lead Product(s) : Enzastaurin,Rituximab,Cyclophosphamide
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Denovo Biopharma
Deal Size : Undisclosed
Deal Type : Partnership
Details : Under the agreement, QIAGEN will develop a diagnostic assay that can detect the Denovo Genomic Marker 1 (DGM1) in DLBCL patients, a biomarker discovered by Denovo that predicts the responsiveness to DB102, also known as enzastaurin.
Brand Name : Kinenza
Molecule Type : Small molecule
Upfront Cash : Undisclosed
December 09, 2021
Lead Product(s) : Enzastaurin,Rituximab,Cyclophosphamide
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Denovo Biopharma
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Enzastaurin
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Aytu BioScience
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Denovo's Licenses DB102 (Enzastaurin) for Rare Genetic Pediatric Onset Disorders to Aytu BioPharma
Details : Aytu BioPharma has acquired substantially all the assets of Rumpus Therapeutics, including Rumpus' option to license DB102 for rare genetic pediatric onset or congenital disorders outside of oncology from Denovo Biopharma LLC.
Brand Name : DB102
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 13, 2021
Lead Product(s) : Enzastaurin
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Aytu BioScience
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Enzastaurin
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Aytu BioScience
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Aytu gains global license to pivotal study-ready protein kinase C β isoform (PKCβ) inhibitor, AR101 (enzastaurin) in rare disease indications. Program initially targeting vascular Ehlers-Danlos Syndrome (vEDS).
Brand Name : AR101
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 12, 2021
Lead Product(s) : Enzastaurin
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Aytu BioScience
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Enzastaurin,Temozolomide
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Grants Fast Track Designation For DB102 in Patients with Newly-Diagnosed Glioblastoma (GBM)
Details : Denovo plans to conduct a randomized, double-blind, placebo-controlled Phase 3 pivotal study of enzastaurin in combination with temozolomide, both during and following radiation therapy, in newly-diagnosed glioblastoma patients.
Brand Name : Kinenza
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 17, 2020
Lead Product(s) : Enzastaurin,Temozolomide
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Enzastaurin
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Rumpus Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Rumpus Therapeutics gains the option to acquire an exclusive license to develop and commercialize DB102 worldwide for rare genetic pediatric onset or congenital disorders outside of oncology.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 21, 2020
Lead Product(s) : Enzastaurin
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Rumpus Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?